International registry on the use of the CytoSorb® adsorber in ICU patients : Study protocol and preliminary results.
S Friesecke, K Träger, G A Schittek...
https://pubmed.ncbi.nlm.nih.gov/28871441/Actively Recruiting
Led by Careggi Hospital · Updated on 2025-02-12
1000
Participants Needed
15
Research Sites
N/A
Total Duration
Researchers are investigating the use of extracorporeal blood purification therapies EBPT in critically ill patients, especially those with acute kidney injury and multiorgan failure. EBPT is commonly used in critical care to remove inflammatory substances from the blood, aiming to improve organ function. However, previous clinical trials have not consistently shown benefits on long-term outcomes like 28-day or hospital mortality. This study aims to identify specific groups of patients who might benefit most from different EBPT membranes by collecting detailed clinical data. This observational study involves critically ill patients receiving various EBPT treatments for kidney support or immune system modulation, using commercial membranes as prescribed by their healthcare providers. Treatments include continuous renal replacement therapy, intermittent hemodialysis, hybrid therapies, and immunomodulation through special membranes that adsorb endotoxins or cytokines. Each center records detailed treatment settings and patient information via a web-based registry accessible on smartphones and tablets, which also provides helpful clinical tools for managing patient care. Participants will be observed throughout their EBPT treatment, with researchers gathering data on clinical and biochemical changes over time, including scoring systems and other patient characteristics. The main outcome is to identify which patient subpopulations benefit most from EBPT, measured 10 days after treatment starts. The registry allows centers to monitor their own results in real time and supports personalized treatment approaches. The study is ongoing and aims to improve understanding of how to tailor EBPT to individual patient needs while enhancing clinical practice through shared data.
CONDITIONS
Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
G
Gianluca Villa, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Careggi Hospital
Lead Sponsor
University of Florence
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Variable depending on individual treatment duration
Participants who undergo routine extracorporeal blood purification therapy (EBPT) with commercial membranes are observed as part of routine clinical care without changes to their treatment.
Visits as per routine clinical care during EBPT
Duration - Up to 10 days after EBPT initiation
Participants are observed and their clinical data are recorded over time to identify subpopulations that benefit from EBPT and to monitor clinical variables during and after therapy.
Data collection integrated with routine care visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
S Friesecke, K Träger, G A Schittek...
https://pubmed.ncbi.nlm.nih.gov/28871441/Salvatore Lucio Cutuli, Antonio Artigas, Roberto Fumagalli...
https://pubmed.ncbi.nlm.nih.gov/27502196/Dinna N Cruz, Massimo Antonelli, Roberto Fumagalli...
https://pubmed.ncbi.nlm.nih.gov/19531784/Didier M Payen, Joelle Guilhot, Yoann Launey...
https://pubmed.ncbi.nlm.nih.gov/25862039/David J Klein, Debra Foster, Christa A Schorr...
https://pubmed.ncbi.nlm.nih.gov/24916483/Careggi Hospital
Lead Sponsor
University of Florence
Collaborating Sponsor